NASDAQ:GANX Gain Therapeutics (GANX) Stock Price, News & Analysis $1.65 -0.14 (-7.82%) Closing price 04:00 PM EasternExtended Trading$1.69 +0.04 (+2.18%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Gain Therapeutics Stock (NASDAQ:GANX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Gain Therapeutics alerts:Sign Up Key Stats Today's Range$1.56▼$1.8050-Day Range$1.65▼$2.7352-Week Range$0.89▼$3.72Volume454,753 shsAverage Volume284,782 shsMarket Capitalization$43.77 millionP/E RatioN/ADividend YieldN/APrice Target$8.20Consensus RatingBuy Company OverviewGain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Read More… Remove Ads Gain Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreGANX MarketRank™: Gain Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 353rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingGain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGain Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Gain Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Gain Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gain Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gain Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGain Therapeutics has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Gain Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.30% of the float of Gain Therapeutics has been sold short.Short Interest Ratio / Days to CoverGain Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gain Therapeutics has recently decreased by 6.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGain Therapeutics does not currently pay a dividend.Dividend GrowthGain Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.30% of the float of Gain Therapeutics has been sold short.Short Interest Ratio / Days to CoverGain Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gain Therapeutics has recently decreased by 6.34%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.07 News SentimentGain Therapeutics has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Gain Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for GANX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gain Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.70% of the stock of Gain Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.97% of the stock of Gain Therapeutics is held by institutions.Read more about Gain Therapeutics' insider trading history. Receive GANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GANX Stock News HeadlinesResearch Analysts Set Expectations for GANX Q1 EarningsApril 3 at 2:21 AM | americanbankingnews.comRoth Capital Forecasts Higher Earnings for Gain TherapeuticsApril 3 at 1:21 AM | americanbankingnews.comTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 4, 2025 | Porter & Company (Ad)Gain Therapeutics (GANX) Receives a Buy from Roth MKMMarch 31, 2025 | markets.businessinsider.comGain Therapeutics (NASDAQ:GANX) Receives Buy Rating from Chardan CapitalMarch 30, 2025 | americanbankingnews.comGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate UpdateMarch 28, 2025 | finanznachrichten.deScotiabank Keeps Their Buy Rating on Gain Therapeutics (GANX)March 28, 2025 | markets.businessinsider.comGain Therapeutics Announces Poster Presentation at AD/PD 2025March 28, 2025 | globenewswire.comSee More Headlines GANX Stock Analysis - Frequently Asked Questions How have GANX shares performed this year? Gain Therapeutics' stock was trading at $2.16 on January 1st, 2025. Since then, GANX stock has decreased by 23.6% and is now trading at $1.65. View the best growth stocks for 2025 here. How were Gain Therapeutics' earnings last quarter? Gain Therapeutics, Inc. (NASDAQ:GANX) released its quarterly earnings data on Thursday, March, 27th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.07. When did Gain Therapeutics IPO? Gain Therapeutics (GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,600,000 shares at a price of $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager. How do I buy shares of Gain Therapeutics? Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gain Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gain Therapeutics investors own include PayPal (PYPL), Pfizer (PFE), SEA (SE), Taiwan Semiconductor Manufacturing (TSM), ZIM Integrated Shipping Services (ZIM), ADC Therapeutics (ADCT) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings3/27/2025Today4/04/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GANX CIK1819411 Webwww.gaintherapeutics.com Phone301-500-1556FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$8.20 High Stock Price Target$12.00 Low Stock Price Target$6.00 Potential Upside/Downside+403.1%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-203.91% Return on Assets-128.05% Debt Debt-to-Equity Ratio0.04 Current Ratio2.99 Quick Ratio2.99 Sales & Book Value Annual Sales$50,000.00 Price / Sales864.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book1.68Miscellaneous Outstanding Shares26,525,000Free Float23,422,000Market Cap$43.24 million OptionableOptionable Beta0.14 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:GANX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.